Tag: Biotech and Pharma

Σύμφωνα με τα στοιχεία που παρουσιάστηκαν, οι πωλήσεις στο πρώτο εξάμηνο κινούνται με ρυθμό ανόδου της τάξης του 24%, επιβεβαιώνοντας τη δυναμική που έχει αναπτύξει ο όμιλος σε βασικές κατηγορίες προϊόντων και αγορές.

 AbbVie said on Monday it would buy biotech Apogee Therapeutics for $10.9 billion, ​in its largest buyout in more than five years to strengthen its next-gen ‌immunology pipeline.

Britain’s second-largest drugmaker GSK has entered an agreement to acquire U.S.-based drugmaker Nuvalent for $10.6 billion to bolster its oncology pipeline, in what would be its largest acquisition in more than a decade.

Eli Lilly shares jumped in premarket trade on Monday, after a late-stage trial of its next-generation weight-loss drug impressed analysts.

Shares of weight loss drug maker Zealand Pharma plummeted as much as 26% on Monday after new data on its experimental medicine raised concerns over its potential side effects.

Moderna said on Monday it has ​partnered with a global health coalition to develop a potential ‌vaccine against Bundibugyo ebolavirus, the strain linked to the ongoing Ebola outbreak in eastern Democratic Republic of Congo.

Η Lavipharm Α.Ε. ανακοινώνει την ολοκλήρωση της συναλλαγής για την απόκτηση των Αδειών Κυκλοφορίας, των εμπορικών σημάτων και των δικαιωμάτων εμπορικής εκμετάλλευσης και παραγωγής του DUROGESIC® από την Janssen Global Services LLC

Eli Lilly & Co. agreed to buy three vaccine developers for a total of up to about $3.8 billion, marking the drugmaker’s re-entry into the infectious disease space.

Biogen (BIIB.O), will advance its experimental Alzheimer’s drug to late-stage ​development after a mid-stage study showed it slowed mental decline and reduced ‌a key brain protein linked to the disease, although it failed to meet the trial’s main goal.

Telehealth company Hims & Hers’ stock plummeted in early trading Tuesday after posting a first-quarter loss and weak earnings guidance for the year ahead.

Novo Nordisk, opens new tab beat first-quarter profit forecasts and nudged up its full-year outlook on Wednesday, helped by stronger-than-expected sales of its new weight-loss pill ‌as it seeks to close the gap with U.S. rival Eli Lilly.

Pfizer shares climbed on Tuesday after the company delivered a first-quarter earnings beat and reaffirmed its full-year outlook.

Moderna defied expectations of a Covid-revenue slowdown on Friday as the drugmaker delivered strong first-quarter results fueled by a surge in international vaccine sales.

Bristol-Myers Squibb reported first-quarter earnings and revenue that topped analyst expectations, and reaffirmed its outlook for the full year.

Shares of Eli Lilly (LLY) rose sharply Thursday after the drugmaker delivered a beat-and-raise quarter driven partly by demand for its GLP-1 drugs.

GSK (GSK) reported higher earnings on increased specialty medicine sales and said it expects to pay a total dividend this year of 70 pence a share.

AstraZeneca (AZN)  beat first-quarter profit expectations and maintained its 2026 forecasts on Wednesday, supported by strong demand for its cancer and rare-disease drugs and investments in the key U.S. and China markets.

Novartis (NOVN) reported a drop in earnings as generic competition for its top-selling heart drug Entresto hit sales in the first months of the year.

Την Ετήσια Ενημέρωση Αναλυτών πραγματοποίησε σήμερα η Lavipharm A.E. σύμφωνα με το Οικονομικό Ημερολόγιο 2026 της Εταιρείας. Η παρουσίαση πραγματοποιήθηκε στο Χρηματιστήριο Αθηνών, στην Ένωση Θεσμικών Επενδυτών.

 Eli Lilly (LLY) said on Monday ‌it would buy privately held blood cancer treatment developer Ajax Therapeutics for up to $2.3 ​billion in cash.